This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in MM patients.~Eligible patients will have their tumor sample analyzed for the prognostic MMprofiler SKY92, several cytogenetic markers, gene expression markers, and gene expression clusters.~A total of 250 patients will be enrolled from up to 9 US centers. Patients will be followed 5 years after diagnosis.
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.